Interestingly, glutamine, the transport substrate of VNUT (SLC17A9), plays a regulatory role in insulin secretion, and therefore, clodronate has been demonstrated to have therapeutic effects on T2D and NASH in mice models (Hasuzawa et al., 2021). Here, SLC17A9 is linked to metabolic dysfunction-associated steatohepatitis.